

# Impact of Moderate-to-Severe Atopic Dermatitis on Daily Functioning among Adolescent Patients: A Real-World Study in the United States

Amy S. Paller,<sup>1</sup> Vimal H. Prajapati,<sup>2</sup> Mercedes E. Gonzalez,<sup>3</sup> Zach Dawson,<sup>4</sup> Evangeline Pierce,<sup>4</sup> Eric Wolf,<sup>4</sup> Niamh Harvey,<sup>5</sup> Oliver Howell,<sup>5</sup> David Bell,<sup>5</sup> Lawrence F. Eichenfield<sup>6</sup>

<sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; <sup>2</sup>Dermatology Research Institute, Skin Health & Wellness Centre, Proby Medical Research, and University of Calgary, Canada; <sup>3</sup>Pediatric Skin Research and University of Miami, Florida, USA; <sup>4</sup>Eli Lilly and Company, Indiana, USA; <sup>5</sup>Adelphi Real-World, Bollington, UK; <sup>6</sup>University of California, San Diego School of Medicine, California, USA

Sponsored by Eli Lilly and Company

## OBJECTIVE

- To understand the impact of AD on daily functioning among adolescent patients with moderate-to-severe AD in the United States.


## CONCLUSION

- These results highlight the profound impact of AD on the daily life of adolescent patients with moderate-to-severe AD, where they or their caregivers report that the patients are feeling self-conscious or embarrassed “all the time” or “sometimes”.
- These disease-associated burdens occur during key developmental milestones in adolescents and can impact the overall course of a patient’s life.
- These findings emphasize the need to carefully assess and consider patients’ quality of life when discussing treatment options.

Fall Clinical Dermatology Conference (Fall CDC) Las Vegas, USA; 23-26 October 2025

## KEY RESULTS

For three out of four patients, patients/caregivers reported feeling self-conscious and embarrassed “all the time” or “sometimes”.



Note: The data for “Rarely” and “Never” were combined. \*n=69 for this outcome; the decrease in the number of patient was because the pen-paper-based questionnaire allowed skipping questions.

## RESULTS

Baseline characteristics of adolescent patients with moderate-to-severe AD.

Characteristics	Patients with moderate-to-severe AD N=70
Age, mean (SD)	14.9 (1.5)
Female, n (%)	33 (47%)
Ethnicity, n (%)	
White	43 (61%)
South/Central American native	9 (13%)
African American	8 (11%)
East/Southeast Asian	6 (9%)
South Asian	3 (4%)
BMI, mean (SD)	22.0 (3.6)
Years since AD diagnosis, *n	*46
Mean (SD)	6.1 (5.3)
Current AD severity, n (%)	
Moderate	48 (69%)
Severe	22 (31%)


This table presents physicians reported demographics for N=70 patients, whom the patients/caregivers reported the impact of AD on daily functioning. \*Data were available for only these patients. Abbreviation: AD: atopic dermatitis; BMI: body mass index.

- Of the 288 patients with moderate-to-severe AD, 70 (24%) of these patients have self-reported or their caregivers have reported the impact of AD on the patient's daily life.

## BACKGROUND

- Atopic dermatitis (AD) is a chronic inflammatory skin condition common in children and adolescents. In the United States (US), its prevalence among adolescents is 9.3%.<sup>1,2</sup>
- AD negatively impact patients' quality of life (QoL), particularly in adolescents, who often undergo significant developmental transitions during this time.<sup>3,4</sup>
- While new treatment options for adolescent patients with moderate-to-severe AD have emerged, there is limited evidence of their real-world impact on patients’ QoL.<sup>5</sup>
- Therefore, it is important to understand the daily functioning of adolescent patients with moderate-to-severe AD.

## STUDY DESIGN AND METHODS



<sup>a</sup>Participation of patients and caregivers was voluntary, and informed consent was obtained.

Abbreviation: AD: atopic dermatitis; DSPTM: Disease Specific Programme; IMS: internal medicine specialist; PCP: Primary care physician.

- Among patients with physician-completed records, these patients and their caregivers self-reported the impact of AD on different areas of patients' daily lives as ‘all the time’, ‘sometimes’, ‘rarely’, and ‘never’.
- Descriptive statistics were used to report the clinical characteristics and impact of AD on daily life.

- This analysis used data from the 2025 Adelphi Pediatric AD Wave II Disease Specific Programme™, which links cross-sectional surveys with retrospective data from patients/caregivers and their consulting physicians in the US.<sup>6-9</sup>
- Patients were 12 to 17 years of age with current moderate-to-severe AD.
- Physicians reported patients’ clinical information, including current AD severity.

**Disclosures:** ASP: Investigator: AbbVie, Biomedics, Dermavant, Eli Lilly and Company (Lilly), Incyte, Johnson & Johnson Innovative Medicine, Regeneron, and UCB; Consultant for Abeona, Arcutis, BioCryst, Boehringer-Ingelheim, Castle Creek, Chiesi, Dermavant, J & J Innovative Medicine, Krystal, LEO, Lilly, L’Oreal, MoonLake Immunotherapeutics, Peltheos, Quoin, Regeneron, and Sanofi; Data safety monitoring board for AbbVie, Abeona, Biocryst, Daiichi Sankyo, and Galderma. VHP: Advisor, consultant, and/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, CIPHER, CorEvitas, Eczema Society of Canada, Lilly, Galderma, GlaxoSmithKline, Homeocean, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, Kenvue, Knight Therapeutics, LEO Pharma, Medexus, Nia Health, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; Investigator for AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Lilly, Galderma, Incyte, J&J Innovative Medicine, Janssen, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; Received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. MEG: Consultant for Arcutis, Lilly, Organon, Pfizer, Regeneron, and Sanofi; Speaker bureaus for Arcutis, Cerave, Lilly, Galderma, Incyte, Regeneron, and Sanofi; Director of American Board of Dermatology. EC, ZD, and EP: Employees and stockholders of Lilly. NH, OH, and DB: Employees of Adelphi Real-world. LFE: Consultant, speaker, advisory board member, or investigator for: AbbVie, Almirall, Amgen, Apogee, Arcutis Biopharmaceuticals, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly and Company, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Takeda, Target RWE, T-Rex, and UCB. Data collection was undertaken by Adelphi Real World as part of an independent survey. Lilly did not influence the original survey through contribution either to the design of questionnaires or data collection. The analysis described here used data from the Adelphi Real World AD DSP. The DSP is a wholly owned Adelphi Real World product. Lilly is one of the multiple subscribers to the DSP. Publication of survey results was not contingent on the subscriber’s approval or censorship of the publication. **Acknowledgments:** Pooja Sagar, an employee of Eli Lilly Services India Pvt. Ltd., provided medical writing support.

## References

- Schoch J, et al. *Pediatrics*. 2025;155(6):e2025071812.
- Silverberg IJ, et al. *Ann Allergy Asthma Immunol*. 2021;26:417–428.
- Children’s National Health System. 2018; *Pediatric Eczema (Atopic Dermatitis): Atopic Dermatitis: Causes, Symptoms, Diagnosis* | National Eczema Association.
- Eichenfield L, et al. *Pediatr Dermatol*. 2025;42:523–531.
- Ferrucci SM, et al. *Dermatol Ther*. 2023;13(5):1071–1081.
- Anderson P, et al. *Curr Med Res Opin*. 2008;24:3063–3072.
- Anderson P, et al. *Curr Med Res Opin*. 2023;39(12):1701–1715.
- Babineaux S, et al. *BMJ Open* 2016;6:e010352.
- Higgins V, et al. *Diabetes Metab Syndr Obes*. 2016;9:371–380.



Scan the QR code for a list of all Lilly content presented at the congress.

Other company and product names are trademarks of their respective owners.